fentanyl transdermal and pentobarbital equally increase sedation. Stay away from or Use Alternate Drug. Restrict use to sufferers for whom alternate treatment method selections are inadequate
Clients stabilized on corticosteroid therapy may possibly demand dosage changes if barbiturates are extra to or withdrawn from their dosage program as a consequence of induction of hepatic microsomal enzymes by barbiturates
pentobarbital will lessen the extent or outcome of buprenorphine, lengthy-acting injection by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Watch Intently. People who transfer to buprenorphine long-acting injection from transmucosal buprenorphine coadministered with CYP3A4 inducers needs to be monitored to be sure buprenorphine plasma degrees are enough.
pentobarbital will lessen the extent or influence of cortisone by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Watch.
Barbiturates can result in fetal destruction when administered to some pregnant female; retrospective, scenario-managed reports have advised a link among maternal consumption of barbiturates and a higher-than-expected incidence of fetal abnormalities
pentobarbital decreases levels of ponatinib by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Prevent or Use Alternate Drug. Prevent Except if the coadministration outweighs the doable possibility of ponatinib underexposure; monitor for indications of lowered efficacy.
pentobarbital and olopatadine intranasal both of those increase sedation. here Steer clear of or Use Alternate Drug. Coadministration increases chance of CNS despair, which may lead to additive impairment of psychomotor general performance and induce daytime impairment.
pentobarbital raises results of ifosfamide by affecting hepatic enzyme CYP2B6 metabolism. Use Caution/Monitor. Coadministration of ifosfamide with CYP2B6 inducers may increase metabolism of ifosfamide to its metabolite. Monitor for amplified consequences/toxicities if coupled with CYP2B6 inducers.
pentobarbital will decrease the level or impact of carvedilol by impacting hepatic enzyme CYP2C9/10 metabolism. Use Warning/Keep an eye on.
Caution when discontinuing CYP3A4 inducers which can be coadministered with hydrocodone; plasma concentrations of hydrocodone could enhance and may lead to likely fatal respiratory depression
benzhydrocodone/acetaminophen and pentobarbital both improve sedation. Stay away from or Use Alternate Drug. Restrict use to clients for whom alternate treatment choices are inadequate
pentobarbital will reduce the level or result of diazepam by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Keep an eye on.
Contraindicated (1)pentobarbital will minimize the level or outcome of lonafarnib by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Lonafarnib is a delicate CYP3A4 substrate. Coadministration with strong or reasonable CYP3A4 inducers is contraindicated.
pentobarbital will reduce the level or impact of almotriptan by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Observe.